TABLE 2.
Papilloma formation and regression in rabbits vaccinated with the E1+E2, E6, and/or E7 gene
| Variable measured | Vaccine | No. of papillomas at CRPV dosea:
|
Total/no. of sitesc | Normb | Pd | ||
|---|---|---|---|---|---|---|---|
| H | M | L | |||||
| No. of papillomase formed | Vector | 11 | 10 | 4 | 25/36 | 1 | 1 |
| E6 | 10 | 4 | 4 | 18/36 | 0.72 | 0.09 | |
| E7 | 6 | 3 | 0 | 9/36 | 0.36 | ∗ | |
| E6+E7 | 9 | 4 | 1 | 14/36 | 0.56 | 0.01 | |
| E1+E2 | 8 | 8 | 2 | 18/36 | 0.72 | 0.09 | |
| E1+E2+E6 | 4 | 3 | 1 | 8/36 | 0.32 | ∗ | |
| E1+E2+E7 | 9 | 4 | 0 | 13/36 | 0.52 | ∗ | |
| E1+E2+E6+E7 | 5 | 4 | 1 | 10/36 | 0.40 | ∗ | |
| No. of papillomase regressed | Vector | 4 | 4 | 1 | 9/25d | 1 | 1 |
| E6 | 7 | 4 | 4 | 15/18 | 2.31 | ∗ | |
| E7 | 4 | 2 | 0 | 6/9 | 1.85 | 0.11 | |
| E6+E7 | 4 | 3 | 1 | 8/14 | 1.59 | NS | |
| E1+E2 | 8 | 8 | 2 | 18/18 | 2.78 | ∗ | |
| E1+E2+E6 | 4 | 3 | 1 | 8/8 | 2.78 | ∗ | |
| E1+E2+E7 | 9 | 4 | 0 | 13/13 | 2.78 | ∗ | |
| E1+E2+E6+E7 | 2 | 1 | 0 | 3/10 | 0.83 | NS | |
| Final frequency of papillomasf | Vector | 7 | 6 | 3 | 16/36e | 1 | 1 |
| E6 | 3 | 0 | 0 | 3/36 | 0.19 | ∗ | |
| E7 | 2 | 1 | 0 | 3/36 | 0.19 | ∗ | |
| E6+E7 | 5 | 1 | 0 | 6/36 | 0.38 | 0.01 | |
| E1+E2 | 0 | 0 | 0 | 0/36 | 0 | ∗ | |
| E1+E2+E6 | 0 | 0 | 0 | 0/36 | 0 | ∗ | |
| E1+E2+E7 | 0 | 0 | 0 | 0/36 | 0 | ∗ | |
| E1+E2+E6+E7 | 3 | 3 | 1 | 7/36 | 0.44 | 0.02 | |
a
Dose of CRPV used for challenge: H, high; M, moderate; L, low.
b
Value normalized to that of the control group (proportion of affected sites).
c
For papilloma formation, values are number of sites that ever formed a papilloma/total number of sites; for papilloma regression, values are number of papillomas that completely regressed/number that formed; and for final frequency, values are final number of papillomas/total number of sites.
d
∗, P < 0.005; NS, not significant.
e
Analyzed by chi-square test.
f
Analyzed by Fisher's exact test.